FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus
Foot and Mouth Disease Virus (FMDV) causes economy losses and is controlled by vaccination in many countries. Vaccine formulations based on empty capsids or Virus-Like Particles (VLPs) have the advantage of avoiding the biological hazard of using infectious FMDV, albeit are poorly immunogenic. Recen...
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | Inglés |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12123/10200 https://www.sciencedirect.com/science/article/abs/pii/S0168170221000460 https://doi.org/10.1016/j.virusres.2021.198339 |
| _version_ | 1855484544731316224 |
|---|---|
| author | Bidart, Juan Esteban Mignaqui, Ana Clara Kornuta, Claudia Alejandra Lupi, Giuliana Gammella, Mariela Soria, Ivana Galarza, Roxana Ivon Ferella, Alejandra Cardillo, Sabrina Beatriz Langellotti, Cecilia Ana Quattrocchi, Valeria Durocher, Yves Wigdorovitz, Andres Marcipar, Ivan Zamorano, Patricia Ines |
| author_browse | Bidart, Juan Esteban Cardillo, Sabrina Beatriz Durocher, Yves Ferella, Alejandra Galarza, Roxana Ivon Gammella, Mariela Kornuta, Claudia Alejandra Langellotti, Cecilia Ana Lupi, Giuliana Marcipar, Ivan Mignaqui, Ana Clara Quattrocchi, Valeria Soria, Ivana Wigdorovitz, Andres Zamorano, Patricia Ines |
| author_facet | Bidart, Juan Esteban Mignaqui, Ana Clara Kornuta, Claudia Alejandra Lupi, Giuliana Gammella, Mariela Soria, Ivana Galarza, Roxana Ivon Ferella, Alejandra Cardillo, Sabrina Beatriz Langellotti, Cecilia Ana Quattrocchi, Valeria Durocher, Yves Wigdorovitz, Andres Marcipar, Ivan Zamorano, Patricia Ines |
| author_sort | Bidart, Juan Esteban |
| collection | INTA Digital |
| description | Foot and Mouth Disease Virus (FMDV) causes economy losses and is controlled by vaccination in many countries. Vaccine formulations based on empty capsids or Virus-Like Particles (VLPs) have the advantage of avoiding the biological hazard of using infectious FMDV, albeit are poorly immunogenic. Recently, we have described that ISPA a new Immune Stimulating Complex adjuvant, is useful to improve the response against FMD of vaccines that use inactivated virus. Now, the adjuvant effects of ISPA and ISA 206 (water/oil/water) on a VLPs-based FMD vaccine were evaluated. VLPs (strain A/Argentina/2001) were obtained in mammalian cell cultures and their elicitation of an immune response against FMDV with and without ISPA or ISA 206 was evaluated in mice as a first approach. Notably, VLPs-ISPA and VLPs-ISA 206 vaccines induced protection against viral challenge in 100 % of mice, while protection induced by VLPs alone was of 40 %. Total and neutralizing FMDV antibodies were higher in the VLPs-ISPA and VLPs-ISA 206 groups compared to the VLPs group. VLPs-ISPA induced significantly higher (p < 0.001) IgG1, IgG2a, IgG2b and IgG3 titers than the VLPs vaccine. Moreover, in comparison with non-adjuvanted VLPs, VLPs-ISPA and VLPs-ISA 206 elicited an increased virus-specific T response, including higher IFNγ+/CD8 + lymphocyte production in mice. When these vaccines were tested in calves, antibody titers reached an Expected Percentage of Protection (EPP) above 90 % in the case of the VLPs-ISPA and VLPs-ISA 206 vaccines, while, in the VLPs group, EPP reached 25 %. IFNγ levels secreted by mononuclear cells of VLP-ISPA-vaccinated cattle were significantly higher than in the VLPs group. Overall, the results demonstrate that VLPs-ISPA or VLPs-ISA 206 are promising formulations for the development of a novel FMD vaccine. |
| format | Artículo |
| id | INTA10200 |
| institution | Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina) |
| language | Inglés |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Elsevier |
| publisherStr | Elsevier |
| record_format | dspace |
| spelling | INTA102002021-09-08T12:13:15Z FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus Bidart, Juan Esteban Mignaqui, Ana Clara Kornuta, Claudia Alejandra Lupi, Giuliana Gammella, Mariela Soria, Ivana Galarza, Roxana Ivon Ferella, Alejandra Cardillo, Sabrina Beatriz Langellotti, Cecilia Ana Quattrocchi, Valeria Durocher, Yves Wigdorovitz, Andres Marcipar, Ivan Zamorano, Patricia Ines Foot-and-mouth Disease Aphthovirus Vaccine Adjuvants Immunity Protection Fiebre Aftosa Virus Fiebre Aftosa Coadyuvantes de Vacunas Inmunidad Protección Foot and Mouth Disease Virus (FMDV) causes economy losses and is controlled by vaccination in many countries. Vaccine formulations based on empty capsids or Virus-Like Particles (VLPs) have the advantage of avoiding the biological hazard of using infectious FMDV, albeit are poorly immunogenic. Recently, we have described that ISPA a new Immune Stimulating Complex adjuvant, is useful to improve the response against FMD of vaccines that use inactivated virus. Now, the adjuvant effects of ISPA and ISA 206 (water/oil/water) on a VLPs-based FMD vaccine were evaluated. VLPs (strain A/Argentina/2001) were obtained in mammalian cell cultures and their elicitation of an immune response against FMDV with and without ISPA or ISA 206 was evaluated in mice as a first approach. Notably, VLPs-ISPA and VLPs-ISA 206 vaccines induced protection against viral challenge in 100 % of mice, while protection induced by VLPs alone was of 40 %. Total and neutralizing FMDV antibodies were higher in the VLPs-ISPA and VLPs-ISA 206 groups compared to the VLPs group. VLPs-ISPA induced significantly higher (p < 0.001) IgG1, IgG2a, IgG2b and IgG3 titers than the VLPs vaccine. Moreover, in comparison with non-adjuvanted VLPs, VLPs-ISPA and VLPs-ISA 206 elicited an increased virus-specific T response, including higher IFNγ+/CD8 + lymphocyte production in mice. When these vaccines were tested in calves, antibody titers reached an Expected Percentage of Protection (EPP) above 90 % in the case of the VLPs-ISPA and VLPs-ISA 206 vaccines, while, in the VLPs group, EPP reached 25 %. IFNγ levels secreted by mononuclear cells of VLP-ISPA-vaccinated cattle were significantly higher than in the VLPs group. Overall, the results demonstrate that VLPs-ISPA or VLPs-ISA 206 are promising formulations for the development of a novel FMD vaccine. Instituto de Virología Fil: Bidart, Juan Esteban. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Bidart, Juan Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Mignaqui, Ana Clara. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; Argentina Fil: Mignaqui, Ana Clara. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Kornuta, Claudia Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Kornuta, Claudia Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Lupi, Giuliana. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas; Argentina Fil: Lupi, Giuliana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Gammella, Mariela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Gammella, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Soria, Ivana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Soria, Ivana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Galarza, Roxana Ivon. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Galarza, Roxana Ivon. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Ferella, Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Ferella, Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Cardillo, Sabrina Beatriz. Biogénesis-Bagó; Argentina Fil: Langellotti, Cecilia Ana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Langellotti, Cecilia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Quattrocchi, Valeria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Quattrocchi, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Durocher, Yves. Human Health Therapeutics Research Center, National Research Council Canada; Canadá Fil: Wigdorovitz, Andres. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Wigdorovitz, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Marcipar, Ivan Sergio. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Tecnología Inmunológica; Argentina Fil: Marcipar, Ivan Sergio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Zamorano, Patricia Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Zamorano, Patricia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Zamorano, Patricia Ines. Universidad del Salvador; Argentina 2021-09-08T12:05:18Z 2021-09-08T12:05:18Z 2021-05 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/10200 https://www.sciencedirect.com/science/article/abs/pii/S0168170221000460 1872-7492 https://doi.org/10.1016/j.virusres.2021.198339 eng info:eu-repograntAgreement/INTA/2019-PD-E5-I105-001/2019-PD-E5-I105-001/AR./Patógenos animales: su interacción con el hospedador y el medio ambiente. Impacto en productividad, ecosistemas, sanidad animal y salud pública en el marco “Una Salud” info:eu-repo/semantics/restrictedAccess application/pdf Elsevier Virus Research 297 : 198339 (Mayo 2021) |
| spellingShingle | Foot-and-mouth Disease Aphthovirus Vaccine Adjuvants Immunity Protection Fiebre Aftosa Virus Fiebre Aftosa Coadyuvantes de Vacunas Inmunidad Protección Bidart, Juan Esteban Mignaqui, Ana Clara Kornuta, Claudia Alejandra Lupi, Giuliana Gammella, Mariela Soria, Ivana Galarza, Roxana Ivon Ferella, Alejandra Cardillo, Sabrina Beatriz Langellotti, Cecilia Ana Quattrocchi, Valeria Durocher, Yves Wigdorovitz, Andres Marcipar, Ivan Zamorano, Patricia Ines FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| title | FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| title_full | FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| title_fullStr | FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| title_full_unstemmed | FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| title_short | FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| title_sort | fmd empty capsids combined with the immunostant particle adjuvant ispa or isa206 induce protective immunity against foot and mouth disease virus |
| topic | Foot-and-mouth Disease Aphthovirus Vaccine Adjuvants Immunity Protection Fiebre Aftosa Virus Fiebre Aftosa Coadyuvantes de Vacunas Inmunidad Protección |
| url | http://hdl.handle.net/20.500.12123/10200 https://www.sciencedirect.com/science/article/abs/pii/S0168170221000460 https://doi.org/10.1016/j.virusres.2021.198339 |
| work_keys_str_mv | AT bidartjuanesteban fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT mignaquianaclara fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT kornutaclaudiaalejandra fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT lupigiuliana fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT gammellamariela fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT soriaivana fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT galarzaroxanaivon fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT ferellaalejandra fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT cardillosabrinabeatriz fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT langellotticeciliaana fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT quattrocchivaleria fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT durocheryves fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT wigdorovitzandres fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT marciparivan fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus AT zamoranopatriciaines fmdemptycapsidscombinedwiththeimmunostantparticleadjuvantispaorisa206induceprotectiveimmunityagainstfootandmouthdiseasevirus |